Evidence map›Paper›PMID 36322484›Full record

ArticleThe Journal of antimicrobial chemotherapy2022

Multiomics characterization of methicillin-resistant Staphylococcus aureus (MRSA) isolates with heterogeneous intermediate resistance to vancomycin (hVISA) in Latin America.

Betsy E Castro, Rafael Rios, Lina P Carvajal, Mónica L Vargas, Mónica P Cala, Lizeth León, Blake Hanson, An Q Dinh, Oscar Ortega-Recalde, Carlos Seas and 5 more

Abstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Comparative proteomic analysis of vancomycin-sensitive and vancomycin-intermediate resistant Staphylococcus aureus.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Betsy E CastroMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia.
Rafael RiosMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia.
Lina P CarvajalMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia.
Mónica L VargasMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia.
Mónica P CalaMetabolomics Core Facility-MetCore, Vice-Presidency for Research, Universidad de los Andes, Bogotá, Colombia.
Lizeth LeónMetabolomics Core Facility-MetCore, Vice-Presidency for Research, Universidad de los Andes, Bogotá, Colombia.
Blake HansonCenter for Infectious Diseases, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA.ORCID 0000-0003-2949-7818
An Q DinhCenter for Infectious Diseases, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA.
Oscar Ortega-RecaldeCenter for Research in Genetics and Genomics-CIGGUR, GENIUROS Research Group, School of Medicine and Health Sciences, Universidad Del Rosario, Bogotá, Colombia.ORCID 0000-0002-8076-0346
Carlos SeasInstituto de Medicina Tropical Alexander Von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.
Jose M MunitaMillennium Initiative for Collaborative Research on Bacterial Resistance (MICROB-R), Santiago, Chile.
Cesar A AriasDivision of Infectious Diseases, Houston Methodist Hospital, Houston, TX, USA.
Sandra RinconMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia.
Jinnethe ReyesMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia.
Lorena DiazMolecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogota, Colombia.

Funding

Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SAVIDGE, TOR C. · 2020 to 2025
$12.0M
VENOUS: A translational study of enterococcal bacteremiaR01AI148342 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2024
$3.9M
The LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7M
POR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5M
Enterococcus faecium virulence: A molecular and therapeutic approachR00AI072961 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2009 to 2010
$593k
Mobile Genetic Elements and Clinical Outcomes in Staphylococcus aureus BacteremiaK01AI148593 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HANSON, BLAKE M · 2020 to 2023
$519k
NIAID NIH HHS K01 AI148593NIAID NIH HHS K24 AI121296NIAID NIH HHS P01 AI152999NIAID NIH HHS R00 AI072961NIAID NIH HHS R01 AI134637NIAID NIH HHS R01 AI148342NIH HHS K01AI148593NIH HHS K24AI121296
6 · The paper itself

Abstract

backgroundHeterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) compromise the clinical efficacy of vancomycin. The hVISA isolates spontaneously produce vancomycin-intermediate Staphylococcus aureus (VISA) cells generated by diverse and intriguing mechanisms.

objectiveTo characterize the biomolecular profile of clinical hVISA applying genomic, transcriptomic and metabolomic approaches.

methods39 hVISA and 305 VSSA and their genomes were included. Core genome-based Bayesian phylogenetic reconstructions were built and alterations in predicted proteins in VISA/hVISA were interrogated. Linear discriminant analysis and a Genome-Wide Association Study were performed. Differentially expressed genes were identified in hVISA-VSSA by RNA-sequencing. The undirected profiles of metabolites were determined by liquid chromatography and hydrophilic interaction in six CC5-MRSA.

resultsGenomic relatedness of MRSA associated to hVISA phenotype was not detected. The change Try38 → His in Atl (autolysin) was identified in 92% of the hVISA. We identified SNPs and k-mers associated to hVISA in 11 coding regions with predicted functions in virulence, transport systems, carbohydrate metabolism and tRNA synthesis. Further, capABCDE, sdrD, esaA, esaD, essA and ssaA genes were overexpressed in hVISA, while lacABCDEFG genes were downregulated. Additionally, valine, threonine, leucine tyrosine, FAD and NADH were more abundant in VSSA, while arginine, glycine and betaine were more abundant in hVISA. Finally, we observed altered metabolic pathways in hVISA, including purine and pyrimidine pathway, CoA biosynthesis, amino acid metabolism and aminoacyl tRNA biosynthesis.

conclusionsOur results show that the mechanism of hVISA involves major changes in regulatory systems, expression of virulence factors and reduction in glycolysis via TCA cycle. This work contributes to the understanding of the development of this complex resistance mechanism in regional strains.

Indexed as

Methicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsAnti-Bacterial AgentsBayes TheoremGenome-Wide Association StudyHumansLatin AmericaMicrobial Sensitivity TestsMultiomicsPhylogenyRNA, TransferStaphylococcus aureusVancomycinVancomycin ResistanceVancomycin-Resistant Staphylococcus aureusAnti-Bacterial AgentsRNA, TransferVancomycin

Identifiers

PMID36322484
PMCPMC10205466

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.